中國海外諾信(00464.HK)盈警:預計中期虧損不少於1310萬港元
格隆匯11月4日丨中國海外諾信(00464.HK)發佈公吿,截至2021年9月30日止六個月,預期集團中期期間將錄得公司股東應占虧損不少於約1310萬港元,而上年同期則錄得公司股東應占虧損約210萬港元。
公吿表示,預期中期期間的虧損將會增加,此主要由於COVID-19疫情持續導致集團產品銷售所得收益減少約23.5%,此情況對歐洲及亞洲市場客户對集團產品的需求產生不利影響;材料成本上漲導致銷售成本增加,尤其是電子及金屬相關部件以及經常開支;及與相應期間相比較,中期期間並無錄得政府補貼約400萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.